Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company's board of directors. With over 30 years of executive management experience overall, including 15 years in CEO roles, he has proven achievements in operations management, acquisitions, licensing, and integration.

Algernon Pharmaceuticals plans to be the first Company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible this year. DMT is a "classic" psychedelic compound part of the tryptamine family.

https://algernonpharmaceuticals.com